Trial reportFrontiers in endocrinology2026
First-in-human pilot trial of G-CSF-mobilised platelet-leukocyte concentrate for severe refractory Asherman syndrome.
Trial report in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Severe refractory Asherman syndrome (SRAS) remains difficult to treat, and the benefit of regenerative blood-derived therapies remains uncertain. This study evaluated whether systemic granulocyte colony-stimulating factor (G-CSF) mobilisation combined with targeted intrauterine delivery of autologous peripheral blood platelet-leukocyte concentrate (PBPLC) could improve endometrial thickness in women with SRAS. Methods: This prospective, single-centre, single-arm pilot study enrolled 10 women with infertility for at least 3 years, severe intrauterine adhesions, poor endometrial development, and failure of previous adhesiolysis, hormonal therapy, and platelet-rich plasma treatment. After G-CSF mobilisation, autologous PBPLC was injected into the endometrial-myometrial junction under hysteroscopic guidance without concurrent formal adhesiolysis. The primary outcome was the change in late pre-ovulatory endometrial thickness (LPO-EMT), analysed using the exact Wilcoxon signed-rank test and Hodges-Lehmann estimates. Results: LPO-EMT increased from 4.6 mm (SD 0.7) to 5.8 mm (SD 1.3), with a Hodges-Lehmann paired difference of 1.08 mm (95% CI 0.45-2.50; p = 0.0039). Hysteroscopic cavity restoration, reduced adhesion severity, and subjective menstrual improvement were observed in all participants, and the AFS score decreased from 10.8 to 4.5. No grade 3 or higher treatment-related adverse events occurred. Among nine women who attempted conception, pregnancy was detected in six (66.7%; exact 95% CI 29.9-92.5), including four clinical pregnancies (44.4%; exact 95% CI 13.7-78.8). However, all clinical pregnancies ended in first-trimester miscarriage, and no ongoing pregnancies or live births were achieved during follow-up. Discussion: These preliminary findings suggest that G-CSF-mobilised autologous PBPLC may be a feasible approach for improving endometrial thickness and uterine cavity restoration in women with SRAS. However, the findings do not establish reproductive efficacy, and larger controlled studies are warranted. Clinical trial registration: https://cris.nih.go.kr/, identifier KCT0004208.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.